The Medical Director at Pfizer Israel, Dr. Alon Rappaport, said Thursday that "the aggressiveness of the Indian variant is not yet known, but the vaccine is also effective against it."
"We are not worried and constantly monitor the vaccine's efficacy data. As long as the vaccine's efficacy is high, probably at rates of over 90% - we do not think it is necessary to update it," said Rappaport.